---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-25-011954"
form_type: "8-K"
ticker: "AVBP"
cik: "0001868279"
company_name: "ArriVent BioPharma, Inc."
filed_at: "2025-09-09T23:59:59+00:00"
generated_at: "2026-05-17T07:21:53.678382+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# ArriVent reports 16.0-month mPFS with firmonertinib in EGFR PACC NSCLC Phase 1b final analysis

## Summary
- Median PFS 16.0 months by BICR with firmonertinib 240 mg once daily in first-line EGFR PACC NSCLC.
- Confirmed ORR 68.2% at 240 mg; median DOR 14.6 months by BICR; responses across multiple PACC mutation types.
- CNS confirmed ORR 42.9% (6/14) with 35.7% CNS complete responses by BICR in evaluable patients.
- First patient enrollment in global pivotal Phase 3 ALPACCA trial expected in H2 2025.
- Safety profile maintained; most common TEAEs: diarrhea, hepatic enzyme elevation, rash; no new signals.

## SEC filing metadata
- accession: 0001558370-25-011954
- form_type: 8-K
- ticker: AVBP
- cik: 0001868279
- company_name: ArriVent BioPharma, Inc.
- filed_at: 2025-09-09T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/0001558370-25-011954-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1868279/000155837025011954/avbp-20250909x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-25-011954
- JSON: https://secwatch.observer/filing/0001558370-25-011954.json
- Plain text: https://secwatch.observer/filing/0001558370-25-011954.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.